Colleen Costello is President and Co-Founder of Vital Vio, a company that designs and manufactures light-based technologies that kill germs and bacteria like MRSA, Salmonella and E. coli, while being safe for humans and animals.
She has been featured on CNBC, Bloomberg News, was named as a 2016 Forbes Magazine 30 Under 30 recipient in Enterprise Technology, 50 Emerging Global Entrepreneurs to Watch by Inc. Magazine, Albany Business Review 40 Under 40 and is a selected member of the Kairos Society.
Colleen's career spans clinical & healthcare research, biomedical engineering, product & business development and management. She has been a researcher on master thesis biochemistry projects at Mount Sinai School of Medicine and Weill Cornell Medical College, NYC, in surgical device design and pre-clinical studies at Covidien Surgical Devices, and tissue engineering research at RPI.
Colleen holds a degree in Biomedical Engineering with a minor in Technological Entrepreneurship from RPI.
Vital Vio has received $700K in investments from SOSVentures and the Eastern New York Angels in 2013 as well as a 2015 round of funding from a variety of groups, including. $650K from NYSERDA.